iShares Neuroscience and Healthcare ETF
The fund will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents as well as in securities not included in the index, but which BFA believes will help the fund track the index. It is non-diversified.
SOURCE: MARKET TAPE & DAILY CREATION/REDEMPTION RECORDS · 6M SHOWN · NET +$2M OVER THIS RANGE
Money keeps arriving — +$2M of net buying over the past month, while the price has returned +27.9% so far this year. At 0.47% a year it is not the cheapest way in — IWM runs the same ground at 0.19%.
COMPOSED FROM THE FUND’S OWN DAILY RECORDS · UPDATED WITH EACH REFRESH
CELL SIZE IS PORTFOLIO WEIGHT · COLOR IS TODAY’S MOVE · TOP 40 POSITIONS
| # | Holding | Weight | Price | Day | 52-wk | |
|---|---|---|---|---|---|---|
| 1 | NEUNEWMARKET | 1.76% | $930.82 | -1.7% | ||
| 2 | PRAXPRAXIS PRECISION MEDICINES | 5.38% | $386.19 | +4.4% | ||
| 3 | DNTHMAGENTA THERAPEUTICS INC | 5.30% | $113.70 | -1.6% | ||
| 4 | ACADACADIA PHARMACEUTICALS | 5.03% | $30.21 | +0.1% | ||
| 5 | SRRKSCHOLAR ROCK HOLDING | 4.56% | $56.51 | +3.3% | ||
| 6 | ARWRARROWHEAD PHARMACEUTICALS | 4.44% | $89.41 | +1.7% | ||
| 7 | XENEXENON PHARMACEUTICALS | 4.51% | $62.32 | -1.4% | ||
| 8 | ALKSALKERMES | 4.27% | $50.18 | +1.4% | ||
| 9 | ARGXARGENX SE | 4.12% | $1032.86 | +4.0% | ||
| 10 | BIIBBIOGEN | 4.02% | $221.56 | +4.2% | ||
| 11 | PTCTPTC THERAPEUTICS | 3.78% | $73.67 | +1.4% | ||
| 12 | DNLIDENALI THERAPEUTICS | 3.56% | $25.69 | +5.7% | ||
| 13 | EWTXEDGEWISE THERAPEUTICS | 3.41% | $46.44 | +5.3% | ||
| 14 | NBIXNEUROCRINE BIOSCIENCES | 3.47% | $155.54 | +0.8% | ||
| 15 | DYNDYNE THERAPEUTICS | 3.38% | $26.78 | +3.0% |
The full book, free with one sign-in.
Top 15 positions are open to everyone. Sign in once and every fund’s complete holdings — plus CSV export, watchlists, and flow alerts — unlock across the network.
Sign in to see all 54| 1 week | +4.0% |
| 1 month | +9.8% |
| 3 months | +20.5% |
| 6 months | +28.8% |
| YTD | +27.9% |
| 1 year | +68.6% |
| 3 years | — |
PRICE RETURN, DISTRIBUTIONS NOT REINVESTED
| 1 week | −$176K |
| 1 month | +$2M |
| 3 months | +$2M |
| YTD | +$2M |
| 1 year | +$2M |
CREATION/REDEMPTION DOLLARS, DAILY RECORDS
The top holding is 5.4% of the book; the top ten carry 45%. Spread across 72+ names, it behaves like roughly 32 equally-weighted positions.
VOLATILITY & DRAWDOWN FROM THE DAILY TAPE · CONCENTRATION FROM THE LATEST DISCLOSED BOOK
| Most-traded holdings, options premium | Bullish | Bearish |
|---|---|---|
| CAPR CAPRICOR THERAPEUTICS | $1M | $759,887 |
| ARGX ARGENX SE | $792,048 | $749,837 |
| BIIB BIOGEN | $578,369 | $455,675 |
| SRPT SAREPTA THERAPEUTICS | $310,851 | $414,630 |
| DNLI DENALI THERAPEUTICS | $328,704 | $337,382 |
TODAY’S OPTIONS PREMIUM IN THE FUND’S UNDERLYING NAMES
Due diligence cuts both ways. These funds sit on the same shelf and beat IBRN on at least one dimension that matters — the fee, the asset base, or where the money is going.
| Fund | Fee | Assets | Flow, 1M | The case | |
|---|---|---|---|---|---|
| IJH iShares Core S&P Mid-Cap ETF | 0.05% | $128.4B | +$547M | -42bp on fee · +$547M in over the month | Head-to-head |
| IDEV iShares Core MSCI International Developed Markets ETF | 0.04% | $32.7B | +$104M | -43bp on fee · +$104M in over the month | Head-to-head |
| IGSB iShares 1-5 Year Investment Grade Corporate Bond ETF | 0.04% | $23.4B | +$520M | -43bp on fee · +$520M in over the month | Head-to-head |
| IGIB iShares 5-10 Year Investment Grade Corporate Bond ETF | 0.04% | $18.7B | +$312M | -43bp on fee · +$312M in over the month | Head-to-head |
| IEFA iShares Core MSCI EAFE ETF | 0.07% | $193.2B | +$631M | -40bp on fee · +$631M in over the month | Head-to-head |